ALZ pilot?
Cornell calls it a P2a (The present study is a Phase 2a, single arm, open label, proof of principle study to evaluate the PET-measured effect on brain inflammation and safety of leronlimab in people with biomarker confirmed mild-to-moderate i.e., mild cognitive impairment/AD)
CYDY has only ALZ P1 on their pipeline chart
We need synchronization.
Cornell calls it a P2a (The present study is a Phase 2a, single arm, open label, proof of principle study to evaluate the PET-measured effect on brain inflammation and safety of leronlimab in people with biomarker confirmed mild-to-moderate i.e., mild cognitive impairment/AD)
CYDY has only ALZ P1 on their pipeline chart
We need synchronization.
7